-
- Remove the Arbitrary Interchangeable Distinction: The Biosimilars Red Tape Elimination Act
- Codify FDA’s Science-Based Approach: The Expedited Access to Biosimilars Act
- Stop Patent Abuse: Eliminating Thickets to Increase Competition (ETHIC) Act
Join Us March 1-3 for Access!
Access! 2027 brings together the industry’s finest to chart the future of generic and biosimilar medicines. Discussions focus on the industry trends and political breakthroughs shaping the backbone of healthcare in the U.S. REGISTER NOW and stay on the cutting edge of generics and biosimilars.
U.S. Generic & Biosimilar Medicines Savings Report
Representing nearly 90% of prescriptions filled but only around 12% of spending, generics and biosimilars are essential to America’s patients and the U.S. healthcare system. The 2026 U.S. Generic & Biosimilar Medicines Savings Report shows – savings are not guaranteed; and will only continue to exist if policymakers and regulators prioritize alleviating the unique challenges impacting this essential industry.
Press Releases
What’s New
Approved Biosimilars in the U.S.
>90
Biosimilars Currently in Development
3.3B
Days of Patient Therapy with Biosimilars
Incremental Days of Biosimilar Therapy
